Emerging drug therapies for systemic lupus erythematosus

Bibliography

• PETRI M: Epidemiology of systemic lupus erythematosus. Best Pract. Res. Clin. Rheumatol. (2002) 16:847-858.
   PubMed Web of Science ®Google Scholar
• MOK CC: Accelerated atherosclerosis, arterial thromboembolism, and preventive strategies in systemic lupus erythematosus. Scand. J. Rheumatol. (2006) 35:85-95.
   PubMed Web of Science ®Google Scholar
• MOK CC, YING KY, NG WL et al.: Long-term outcome of diffuse proliferative lupus glomerulonephritis treated with cyclophosphamide. Am. J. Med. (2006) 119:355 e25-e33.
   PubMed Web of Science ®Google Scholar
• ALARCON GS, BASTIAN HM, BEASLEY TM et al.; LUMINA STUDY GROUP: Systemic lupus erythematosus in a multi-ethnic cohort (LUMINA) XXXII: contributions of admixture and socioeconomic status to renal involvement. Lupus (2006) 15:26-31.
   PubMed Web of Science ®Google Scholar
• MOK CC, WONG RWS, LAU CS: Lupus nephritis in southern Chinese patients: clinicopathological findings and long term outcome. Am. J. Med. (1999) 34:315-323.
   Google Scholar
• MOK CC, WONG RWS, LAI KN: Treatment of severe proliferative lupus nephritis: the current state. Ann. Rheum. Dis. (2003) 62:799-804.
   PubMed Web of Science ®Google Scholar
• MOK CC: Update on the therapies of severe lupus nephritis. Curr. Rheumatol. Rev. (2006) 2:186-190.
   Google Scholar
• NO AUTHORS LISTED: American College of Rheumatology nomenclature and case definitions for neuropsychiatric lupus syndromes. Arthritis Rheum. (1999) 42:599-608.
   PubMed Web of Science ®Google Scholar
• MOK CC, TO CH, MAK A: Neuropsychiatric damage in southern Chinese patients with systemic lupus erythematosus. Medicine (Balimore) 85(4):221-228.
   PubMed Web of Science ®Google Scholar
• NEUWELT CM, LACKS S, KAYE BR, ELLMAN JB, BORENSTEIN DG: Role of intravenous cyclophosphamide in the treatment of severe neuropsychiatric systemic lupus erythematosus. Am. J. Med. (1995) 98:32-41.
   PubMed Web of Science ®Google Scholar
• BARILE-FABRIS L, ARIZA-ANDRACA R, OLGUIN-ORTEGA L et al.: Controlled clinical trial of IV cyclophosphamide versus IV methylprednisolone in severe neurological manifestations in systemic lupus erythematosus. Ann. Rheum. Dis. (2005) 64:620-625.
   PubMed Web of Science ®Google Scholar
• MOK CC, LAU CS, WONG RWS: Treatment of lupus psychosis with oral cyclophosphamide followed by azathioprine maintenance: an open study. Am. J. Med. (2003) 115:59-62.
   PubMed Web of Science ®Google Scholar
• MOK CC, MAK A, TO CH: Mycophenolate mofetil for lupus-related myelopathy. Ann. Rheum. Dis. (2006) 65:971-973.
   PubMed Web of Science ®Google Scholar
• PETRI M, JONES RJ, BRODSKY RA: High-dose cyclophosphamide without stem cell transplantation in systemic lupus erythematosus. Arthritis Rheum. (2003) 48:166-173.
   PubMed Web of Science ®Google Scholar
• BOUMPAS DT, CHROUSOS GP, WILDER RL, CUPPS TR, BALOW JE: Glucocorticoid therapy for immune-mediated diseases: basic and clinical correlates. Ann. Intern. Med. (1993) 119:1198-1208.
   PubMed Web of Science ®Google Scholar
• HEROLD MJ, MCPHERSON KG, REICHARDT HM: Glucocorticoids in T cell apoptosis and function. Cell. Mol. Life Sci. (2006) 63:60-72.
   PubMed Web of Science ®Google Scholar
• ABU-SHAKRA M, SHOENFELD Y: Azathioprine therapy for patients with systemic lupus erythematosus. Lupus (2001) 10:152-153.
   PubMed Web of Science ®Google Scholar
• AUSTIN HA III, KLIPPEL JH, BALOW JE et al.: Therapy of lupus nephritis. Controlled trial of prednisone and cytotoxic drugs. N. Engl. J. Med. (1986) 314:614-619.
   PubMed Web of Science ®Google Scholar
• BOUMPAS DT, AUSTIN HA III, VAUGHN EM et al.: Controlled trial of pulse methylprednisolone versus two regimens of pulse cyclophosphamide in severe lupus nephritis. Lancet (1992) 340:741-745.
   PubMed Web of Science ®Google Scholar
• MOK CC, HO CTK, CHAN KW et al.: Outcome and prognostic indicators of diffuse proliferative lupus glomerulonephritis treated with sequential oral cyclophosphamide and azathioprine. Arthritis Rheum. (2002) 46:1003-1013.
   PubMed Web of Science ®Google Scholar
• CHAN TM, TSE KC, TANG CS, LAI KN, LI FK: Long-term outcome of patients with diffuse proliferative lupus nephritis treated with prednisolone and oral cyclophosphamide followed by azathioprine. Lupus (2005) 14:265-272.
   PubMed Web of Science ®Google Scholar
• MOK CC, YING KY, TANG S et al.: Predictors and outcome of renal flares after successful cyclophosphamide treatment for diffuse proliferative lupus glomerulonephritis. Arthritis Rheum. (2004) 50:2559-2568.
   PubMed Web of Science ®Google Scholar
• HOUSSIAU FA, VASCONCELOS C, D’CRUZ D et al.: Early response to immunosuppressive therapy predicts good renal outcome in lupus nephritis: lessons from the long-term follow-up of the Euro-Lupus Nephritis Trial. Arthritis Rheum. (2004) 50:3934-3940.
   PubMed Web of Science ®Google Scholar
• TAM LS, LI EK, LEUNG CB et al.: Long-term treatment of lupus nephritis with cyclosporin A. QJM (1998) 91:573-580.
   PubMed Web of Science ®Google Scholar
• NO AUTHORS LISTED: A randomized study of the effect of withdrawing hydroxychloroquine sulfate in systemic lupus erythematosus. The Canadian Hydroxychloroquine Study Group. N. Engl. J. Med. (1991) 324:150-154.
   PubMed Web of Science ®Google Scholar
• PETRI M: Hydroxychloroquine use in the Baltimore Lupus Cohort: effects on lipids, glucose and thrombosis. Lupus (1996) 5(Suppl. 1):S16-S22.
   PubMedGoogle Scholar
• WONG JM, ESDAILE JM: Methotrexate in systemic lupus erythematosus. Lupus (2005) 14:101-105.
   PubMed Web of Science ®Google Scholar
• CARNEIRO JR, SATO EI: Double blind, randomized, placebo controlled clinical trial of methotrexate in systemic lupus erythematosus. J. Rheumatol. (1999) 26:1275-1279.
   PubMed Web of Science ®Google Scholar
• TOUBI E, KESSEL A, SHOENFELD Y: High-dose intravenous immunoglobulins: an option in the treatment of systemic lupus erythematosus. Hum. Immunol. (2005) 66:395-402.
   PubMed Web of Science ®Google Scholar
• BOLETIS JN, IOANNIDIS JP, BOKI KA, MOUTSOPOULOS HM: Intravenous immunoglobulin compared with cyclophosphamide for proliferative lupus nephritis. Lancet (1999) 354:569-570.
   PubMed Web of Science ®Google Scholar
• ORBACH H, TISHLER M, SHOENFELD Y: Intravenous immunoglobulin and the kidney – a two-edged sword. Semin. Arthritis Rheum. (2004) 34:593-601.
   PubMed Web of Science ®Google Scholar
• WINDER A, MOLAD Y, OSTFELD I, KENET G, PINKHAS J, SIDI Y: Treatment of systemic lupus erythematosus by prolonged administration of high dose intravenous immunoglobulin: report of 2 cases. J. Rheumatol. (1993) 20:495-498.
   PubMed Web of Science ®Google Scholar
• RENAL DISEASE SUBCOMMITTEE OF THE AMERICAN COLLEGE OF RHEUMATOLOGY AD HOC COMMITTEE ON SYSTEMIC LUPUS ERYTHEMATOSUS RESPONSE CRITERIA: The American College of Rheumatology response criteria for proliferative and membranous renal disease in systemic lupus erythematosus clinical trials. Arthritis Rheum. (2006) 54:421-432.
   PubMed Web of Science ®Google Scholar
• WIESENDANGER M, STANEVSKY A, KOVSKY S, DIAMOND B: Novel therapeutics for systemic lupus erythematosus. Curr. Opin. Rheumatol. (2006) 18:227-235.
   PubMed Web of Science ®Google Scholar
• MOK CC, LAU CS: Pathogenesis of SLE. J. Clin. Pathol. (2003) 56:481-490.
   PubMed Web of Science ®Google Scholar
• KIROU KA, SALMON JE, CROW MK: Soluble mediators as therapeutic targets in systemic lupus erythematosus: cytokines, immunoglobulin receptors, and the complement system. Rheum. Dis. Clin. North Am. (2006) 32:103-119.
   PubMed Web of Science ®Google Scholar
• MOK CC, LAI KN: Mycophenolate mofetil in lupus glomerulonephritis. Am. J. Kidney Dis. (2002) 40:447-457.
   PubMed Web of Science ®Google Scholar
• MAK A, MOK CC: Mycophenolate mofetil for refractory haemolytic anemia in systemic lupus erythematosus. Lupus (2005) 14:856-858.
   PubMed Web of Science ®Google Scholar
• SCHANZ S, ULMER A, RASSNER G, FIERLBECK G: Successful treatment of subacute cutaneous lupus erythematosus with mycophenolate mofetil. Br. J. Dermatol. (2002) 147:174-178.
   PubMed Web of Science ®Google Scholar
• GLICKLICH D, ACHARYA A: Mycophenolate mofetil therapy for lupus nephritis refractory to intravenous cyclophosphamide. Am. J. Kidney Dis. (1998) 32:318-322.
   PubMed Web of Science ®Google Scholar
• BURATTI S, SZER IS, SPENCER CH, BARTOSH S, REIFF A: Mycophenolate mofetil treatment of severe renal disease in pediatric onset systemic lupus erythematosus. J. Rheumatol. (2001) 28:2103-2108.
   PubMed Web of Science ®Google Scholar
• DOOLEY MA, COSIO FG, NACHMAN PH et al.: Mycophenolate mofetil therapy in lupus nephritis: clinical observations. J. Am. Soc. Nephrol. (1999) 10:833-839.
   PubMed Web of Science ®Google Scholar
• KARIM MY, PISONI CN, FERRO L et al.: Reduction of proteinuria with mycophenolate mofetil in predominantly membranous lupus nephropathy. Rheumatology (Oxford) (2005) 44:1317-1321.
   PubMed Web of Science ®Google Scholar
• KAPITSINOU PP, BOLETIS JN, SKOPOULI FN, BOKI KA, MOUTSOPOULOS HM: Lupus nephritis: treatment with mycophenolate mofetil. Rheumatology (Oxford) (2004) 43:377-380.
   PubMed Web of Science ®Google Scholar
• CHAN TM, LI FK, TANG CS et al.: Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis. Hong Kong-Guangzhou Nephrology Study Group. N. Engl. J. Med. (2000) 343:1156-1162.
   PubMed Web of Science ®Google Scholar
• ONG LM, HOOI LS, LIM TO et al.: Randomized controlled trial of pulse intravenous cyclophosphamide versus mycophenolate mofetil in the induction therapy of proliferative lupus nephritis. Nephrology (Carlton) (2005) 10:504-510.
   PubMed Web of Science ®Google Scholar
• GINZLER EM, DOOLEY MA, ARANOW C et al.: Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis. N. Engl. J. Med. (2005) 353:2219-2228.
   PubMed Web of Science ®Google Scholar
• CHAN TM, TSE KC, TANG CS, MOK MY, LI FK; HONG KONG NEPHROLOGY STUDY GROUP: Long-term study of mycophenolate mofetil as continuous induction and maintenance treatment for diffuse proliferative lupus nephritis. J. Am. Soc. Nephrol. (2005) 16:1076-1084.
   PubMed Web of Science ®Google Scholar
• CONTRERAS G, PARDO V, LECLERCQ B et al.: Sequential therapies for proliferative lupus nephritis. N. Engl. J. Med. (2004) 350:971-980.
   PubMed Web of Science ®Google Scholar
• POLITT D, HEINTZ B, FLOEGE J, MERTENS PR: Tacrolimus (FK-506)-based immunosuppression in severe systemic lupus erythematosus. Clin. Nephrol. (2004) 62:49-53.
   PubMed Web of Science ®Google Scholar
• MOK CC, TONG KH, TO CH, SIU YP, AU TC: Tacrolimus for induction therapy of diffuse proliferative lupus nephritis: an open-labeled pilot study. Kidney Int. (2005) 68:813-817.
   PubMed Web of Science ®Google Scholar
• REMER CF, WEISMAN MH, WALLACE DJ: Benefits of leflunomide in systemic lupus erythematosus: a pilot observational study. Lupus (2001) 10:480-483.
   PubMed Web of Science ®Google Scholar
• PETERA P, MANDER B, MANGER K et al.: A pilot study of leflunomide in systemic lupus erythematosus. Arthritis Rheum. (2001) 48:S241.
   Google Scholar
• TAM LS, LI EK, WONG CK, LAM CW, SZETO CC: Double-blind, randomized, placebo-controlled pilot study of leflunomide in systemic lupus erythematosus. Lupus (2004) 13:601-604.
   PubMed Web of Science ®Google Scholar
• TAM LS, LI EK, WONG CK, LAM CWK, SZETO CC: Safety and efficacy of leflunomide in the treatment of lupus nephritis refractory or intolerant to traditional immunosuppressive therapy: an open-label trial. Ann. Rheum. Dis. (2006) 65:417-418.
   PubMed Web of Science ®Google Scholar
• GENSBURGER D, KAWASHIMA M, MAROTTE H, KANITAKIS J, MIOSSEC P: Lupus erythematosus with leflunomide: induction or reactivation? Ann. Rheum. Dis. (2005) 64:153-155.
   PubMed Web of Science ®Google Scholar
• GOEB V, BERTHELOT JM, JOLY P et al.: Leflunomide-induced subacute cutaneous lupus erythematosus. Rheumatology (Oxford) (2005) 44:823-824.
   PubMed Web of Science ®Google Scholar
• VAN VOLLENHOVEN RF, ENGLEMAN EG, MCGUIRE JL: An open study of dehydroepiandrosterone in systemic lupus erythematosus. Arthritis Rheum. (1994) 37:1305-1310.
   PubMed Web of Science ®Google Scholar
• VAN VOLLENHOVEN RF, ENGLEMAN EG, MCGUIRE JL: Dehydroepiandrosterone in systemic lupus erythematosus: results of a doubleblind, placebo-controlled, randomized clinical trial. Arthritis Rheum. (1995) 38:1826-1831.
   PubMed Web of Science ®Google Scholar
• PETRI MA, LAHITA RG, VAN VOLLENHOVEN RF et al.; for the GL-701 STUDY GROUP: Effects of prasterone on corticosteroid requirements of women with systemic lupus erythematosus: a double-blind, randomized, placebo-controlled trial. Arthritis Rheum. (2002) 46:1820-1829.
   PubMed Web of Science ®Google Scholar
• CHANG DM, LAN JL, LIN HY, LUO SF: Dehydroepiandrosterone treatment of women with mild-to-moderate systemic lupus erythematosus: a multicenter randomized, double-blind, placebo-controlled trial. Arthritis Rheum. (2002) 46:2924-2927.
   PubMed Web of Science ®Google Scholar
• PETRI MA, MEASE PJ, MERRILL JT et al.: Effects of prasterone on disease activity and symptoms in women with active systemic lupus erythematosus. Arthritis Rheum. (2004) 50:2858-2868.
   PubMed Web of Science ®Google Scholar
• BOUMPAS DT, TASSIULAS IO, FLEISHER TA et al.: A pilot study of low-dose fludarabine in membranous nephropathy refractory to therapy. Clin. Nephrol. (1999) 52:67-75.
   PubMed Web of Science ®Google Scholar
• DAVIS JC Jr, AUSTIN H III, BOUMPAS D et al. : A pilot study of 2-chloro-2′-deoxyadenosine in the treatment of systemic lupus erythematosus-associated glomerulonephritis. Arthritis Rheum. (1998) 41:335-343.
   PubMed Web of Science ®Google Scholar
• LEANDRO MJ, CAMBRIDGE G, EDWARDS JC, EHRENSTEIN MR, ISENBERG DA: B-cell depletion in the treatment of patients with systemic lupus erythematosus: a longitudinal analysis of 24 patients. Rheumatology (Oxford) (2005) 44:1542-1545.
   PubMed Web of Science ®Google Scholar
• MARKS SD, PATEY S, BROGAN PA et al.: B lymphocyte depletion therapy in children with refractory systemic lupus erythematosus. Arthritis Rheum. (2005) 52:3168-3174.
   PubMed Web of Science ®Google Scholar
• GOTTENBERG JE, GUILLEVIN L, LAMBOTTE O et al.: Tolerance and short term efficacy of rituximab in 43 patients with systemic autoimmune diseases. Ann. Rheum. Dis. (2005) 64:913-920.
   PubMed Web of Science ®Google Scholar
• VAN VOLLENHOVEN RF, GUNNARSSON I, WELIN-HENRIKSSON E et al.: Biopsy-verified response of severe lupus nephritis to treatment with rituximab (anti-CD20 monoclonal antibody) plus cyclophosphamide after biopsy-documented failure to respond to cyclophosphamide alone. Scand. J. Rheumatol. (2004) 33:423-427.
   PubMed Web of Science ®Google Scholar
• VIGNA-PEREZ M, HERNANDEZ-CASTRO B, PAREDES-SAHAROPULOS O et al.: Clinical and immunological effects of Rituximab in patients with lupus nephritis refractory to conventional therapy: a pilot study. Arthritis Res. Ther. (2006) 8:R83.
   PubMed Web of Science ®Google Scholar
• LOONEY RJ, ANOLIK JH, CAMPBELL D et al.: B cell depletion as a novel treatment for systemic lupus erythematosus: a Phase I/II dose-escalation trial of rituximab. Arthritis Rheum. (2004) 50:2580-2589.
   PubMed Web of Science ®Google Scholar
• LAMBOTTE O, DURBACH A, KOTB R, FERLICOT S, DELFRAISSY JF, GOUJARD C: Failure of rituximab to treat a lupus flare-up with nephritis. Clin. Nephrol. (2005) 64:73-77.
   PubMed Web of Science ®Google Scholar
• EDELBAUER M, JUNGRAITHMAYR T, ZIMMERHACKL LB: Rituximab in childhood systemic lupus erythematosus refractory to conventional immunosuppression: case report. Pediatr. Nephrol. (2005) 20:811-813.
   PubMed Web of Science ®Google Scholar
• CARTRON G, DACHEUX L, SALLES G et al.: Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. Blood (2002) 99:754-758.
   PubMed Web of Science ®Google Scholar
• KAUFMANN J, WEGENER WA, HORAK ID et al.: Initial clinical study of immunotherapy in sle using epratuzumab (humanized anti-CD22 antibody). Arthritis Rheum. (2004) 49:Abstract 1127.
   Google Scholar
• FURIE R, STOHL W, GINZLER E et al.: Safety, pharmacokinetic and pharmacodynamic results of a Phase I single and double doseescalation study of Lymphostat-B (human monoclonal antibody to BLyS) in SLE patients. Arthritis Rheum. (2003) 48:abstract 922.
   Google Scholar
• FURIE RA, CASH JM, CRONIN ME et al.: Treatment of systemic lupus erythematosus with LJP-394. J. Rheumatol. (2001) 28:257-265.
   PubMed Web of Science ®Google Scholar
• ALARCON-SEGOVIA D, TUMLIN JA, FURIE RA et al.: LJP-394 for the prevention of renal flare in patients with systemic lupus erythematosus: results from a randomized, double-blind, placebo-controlled study. Arthritis Rheum. (2003) 48:442-454.
   PubMed Web of Science ®Google Scholar
• FINCK BK, LINSLEY PS, WOFSY D: Treatment of murine lupus with CTLA4Ig. Science (1994) 265:1225-1227.
   PubMed Web of Science ®Google Scholar
• DAIKH DI, WOFSY D: Cutting edge: reversal of murine lupus nephritis with CTLA4Ig and cyclophosphamide. J. Immunol. (2001) 166:2913-2916.
   PubMed Web of Science ®Google Scholar
• DAIKH DI, FINCK BK, LINSLEY PS, HOLLENBAUGH D, WOFSY D: Long-term inhibition of murine lupus by brief simultaneous blockade of the B7/CD28 and CD40/gp39 costimulation pathways. J. Immunol. (1997) 159:3104-3108.
   PubMed Web of Science ®Google Scholar
• DAVIS JC Jr, TOTORITIS MC, ROSENBERG J, SKLENAR TA, WOFSY D: Phase I clinical trial of a monoclonal antibody against CD40-ligand (IDEC-131) in patients with systemic lupus erythematosus. J. Rheumatol. (2001) 28:95-101.
   PubMed Web of Science ®Google Scholar
• KALUNIAN KC, DAVIS JC Jr, MERRILL JT, TOTORITIS MC, WOFSY D; IDEC-131 LUPUS STUDY GROUP: Treatment of systemic lupus erythematosus by inhibition of T cell costimulation with anti-CD154: a randomized, double-blind, placebo-controlled trial. Arthritis Rheum. (2002) 46:3251-3258.
   PubMed Web of Science ®Google Scholar
• BOUMPAS DT, FURIE R, MANZI S et al.; BG-9588 LUPUS NEPHRITIS TRIAL GROUP: A short course of BG-9588 (anti-CD40 ligand antibody) improves serologic activity and decreases hematuria in patients with proliferative lupus glomerulonephritis. Arthritis Rheum. (2003) 48:719-727.
   PubMed Web of Science ®Google Scholar
• ISHIDA H, MUCHAMUEL T, SAKAGUCHI S, ANDRADE S, MENON S, HOWARD M: Continuous administration of anti-interleukin 10 antibodies delays onset of autoimmunity in NZB/W F1 mice. J. Exp. Med. (1994) 179:305-310.
   PubMed Web of Science ®Google Scholar
• LLORENTE L, RICHAUD-PATIN Y, GARCIA-PADILLA C et al.: Clinical and biological effects of anti-interleukin-10 monoclonal antibody administration in systemic lupus erythematosus. Arthritis Rheum. (2000) 43:1790-1800.
   PubMed Web of Science ®Google Scholar
• ANOLIK JH, ARINGER M: New treatments for SLE: cell-depleting and anti-cytokine therapies. Best Pract. Res. Clin. Rheumatol. (2005) 19:859-878.
   PubMed Web of Science ®Google Scholar
• ARINGER M, GRANINGER WB, STEINER G, SMOLEN JS: Safety and efficacy of tumor necrosis factor alpha blockade in systemic lupus erythematosus: an open-label study. Arthritis Rheum. (2004) 50:3161-3169.
   PubMed Web of Science ®Google Scholar
• LINKER-ISRAELI M, DEANS RJ, WALLACE DJ, PREHN J, OZERI-CHEN T, KLINENBERG JR: Elevated levels of endogenous IL-6 in systemic lupus erythematosus. A putative role in pathogenesis. J. Immunol. (1991) 147:117-123.
   PubMed Web of Science ®Google Scholar
• FINCK BK, CHAN B, WOFSY D: Interleukin 6 promotes murine lupus in NZB/NZW F1 mice. J. Clin. Invest. (1994) 94:585-591.
   PubMed Web of Science ®Google Scholar
• MIHARA M, TAKAGI N, TAKEDA Y, OHSUGI Y: IL-6 receptor blockage inhibits the onset of autoimmune kidney disease in NZB/W F1 mice. Clin. Exp. Immunol. (1998) 112:397-402.
   PubMed Web of Science ®Google Scholar
• WANG Y, HU Q, MADRI JA, ROLLINS SA, CHODERA A, MATIS LA: Amelioration of lupus-like autoimmune disease in NZB/WF1 mice after treatment with a blocking monoclonal antibody specific for complement component C5. Proc. Natl. Acad. Sci. USA (1996) 93:8563-8568.
   PubMed Web of Science ®Google Scholar
• ROTHER RP, MOJCIK CF, MCCROSKERY EW: Inhibition of terminal complement: a novel therapeutic approach for the treatment of systemic lupus erythematosus. Lupus (2004) 13:328-334.
   PubMed Web of Science ®Google Scholar
• PAVLETIC SZ, ILLEI GG: The role of immune ablation and stem cell transplantation in severe SLE. Best Pract. Res. Clin. Rheumatol. (2005) 19:839-858.
   PubMed Web of Science ®Google Scholar
• JAYNE D, PASSWEG J, MARMONT A et al.: Autologous stem cell transplantation for systemic lupus erythematosus. Lupus (2004) 13:168-176.
   PubMed Web of Science ®Google Scholar
• BRODSKY RA, PETRI M, SMITH BD et al.: Immunoablative high-dose cyclophosphamide without stem-cell rescue for refractory, severe autoimmune disease. Ann. Intern. Med. (1998) 129:1031-1035.
   PubMed Web of Science ®Google Scholar
• PETRI M, JONES RJ, BRODSKY RA: High-dose cyclophosphamide without stem cell transplantation in systemic lupus erythematosus. Arthritis Rheum. (2003) 48:166-173.
   PubMed Web of Science ®Google Scholar
• PETRI M, BRODSKY R, JONES R, BRODSKY I, MAGDER L: High-dose cyclophosphamide versus monthly cyclophosphamide: eighteen month results. Arthritis Rheum. (2005) 50:Abstract 1993.
   Google Scholar